Palisade Bio (PALI) Share-based Compensation (2010 - 2026)
Palisade Bio (PALI) posted quarterly Share-based Compensation of $4.3 million for Q1 2026, up 7438.6% year-over-year from $57000.0 in Q1 2025, and up 15.45% quarter-over-quarter from $3.7 million in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Share-based Compensation (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Share-based Compensation for 17 consecutive years, with $4.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 7438.6% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $7.6 million (up 4813.58% YoY), while the FY2025 annual figure was $3.9 million, up 1862.0% from the prior year.
- Share-based Compensation advanced to $4.3 million in Q1 2026 per PALI's latest filing, from $3.7 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $4.3 million in Q1 2026 and bottomed at -$440000.0 in Q4 2024.
- Historically, Share-based Compensation has averaged $589470.6 across 5 years, with a median of $185000.0 in 2023.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 337.84% — and 2026, when it soared 7438.6%.
- Palisade Bio's Share-based Compensation stood at $86000.0 in 2022, then jumped by 115.12% to $185000.0 in 2023, then tumbled by 337.84% to -$440000.0 in 2024, then jumped by 945.91% to $3.7 million in 2025, then climbed by 15.45% to $4.3 million in 2026.
- Business Quant data shows PALI's Share-based Compensation at $4.3 million in Q1 2026, $3.7 million in Q4 2025, and $200000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | 4.78 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.78 Mn |
| Mar 31, 2026 | 4.30 Mn |
| Dec 31, 2025 | 3.73 Mn |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 60,000.00 |
| Mar 31, 2025 | 69,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 92,000.00 |
| Jun 30, 2024 | 358,000.00 |
| Mar 31, 2024 | 118,000.00 |
| Dec 31, 2023 | 185,000.00 |
| Sep 30, 2023 | 543,188.00 |
| Jun 30, 2023 | 468,188.00 |
| Mar 31, 2023 | 93,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Sep 30, 2022 | 2.59 Mn |
| Jun 30, 2022 | 2.66 Mn |
| Mar 31, 2022 | 2.46 Mn |
| Dec 31, 2021 | 683,000.00 |
| Sep 30, 2021 | 799,562.00 |